Table of Contents
| << Previous Issue | Jul 2012 (Vol: 2012, Issue: 7) | Next Issue >> |
- Section: Licensing
-
AstraZeneca Signs Second Licence Agreement with Rigel for Preclinical Asthma Drug
-
Roche and Seaside Therapeutics Collaborate to Develop Disease-Modifying Therapies for Neurodevelopmental Disorders
-
Ferring Licenses Late-Stage Constipation Drug from AstraZeneca Spinout Albireo
-
Russia’s SatRx Licenses Exclusive Rights to Pfizer’s DPP-IV Inhibitor
-
Evotec, Harvard and Janssen Form Three-Way Collaboration in Beta Cell Regeneration
-
Merck & Co. Strengthens its HIV Pipeline with Two Licensing Deals
-
Boehringer Ingelheim Adds Phase II Anti-Inflammatory Drug to its Respiratory Disease Pipeline
- Section: Mergers & Acquisitions
-
BMS Teams Up with AstraZeneca to Buy Amylin for US$7 B
-
GlaxoSmithKline Secures Human Genome Sciences Takeover with Sweetened Offer
- Section: Research & Development
-
Biogen Idec and Isis Pharmaceuticals Sign Second Rare Disease Option Agreement
-
AstraZeneca Signs Two Deals to Advance its Virtual Neuroscience R&D Strategy
-
Genmab Further Validates its DuoBody™ Technology with Janssen Biotech Agreement
PharmaDeals has now moved to a new platform (https://analyticslink.customerportal.iqvia.com). The current PharmaDeals website will be disabled from October 31, 2026. Please update your bookmarks and, if you have any issues accessing the new platform, please contact your IQVIA account manager.
RSS